• Atezolizumab
  • Atezolizumab

Atezolizumab

Login for price

Sorry! Our Atezolizumab is currently sold out.

Want to be notified when it becomes available again? Simply register your interest and we'll send you a message when it does.

Login for Price
Free Delivery
Lorem Ipsum dummy
Big Savings
Lorem Ipsum dummy
Customer Care
Lorem Ipsum dummy
Gift Voucher
Lorem Ipsum dummy

Active Ingredient: Atezolizumab

Therapeutic Class: Monoclonal Antibody (anti-PD-L1)

Indications: Non-small cell lung cancer, urothelial carcinoma, triple-negative breast cancer, and others

Dosage Form: Intravenous infusion

Manufacturer: Roche (Switzerland)

Administration Advice: Given via IV infusion every 2–3 weeks; monitor for immune-related adverse effects

Certification / Approval Status: Approved in the United States, European Union, Japan, and other countries

Special Notes: Requires cold chain storage (2–8°C); immunotherapy-related side effects possible